Volume 10 Number 1 2026
Moving Beyond the Double-Strand Break Through CRISPR-Based Epigenome Editing for Specificity-Driven Sickle Cell Disease Therapy
Johnson Stanslas1, Amir Imran Faisal Hamdi1, Saiful Effendi Syafruddin2
Integrative Biomedical Research 10 (1) 1-8 https://doi.org/10.25163/biomedical.10110920
Submitted: 14 December 2025 Revised: 07 February 2026 Accepted: 16 February 2026 Published: 18 February 2026
Sickle cell disease (SCD) remains one of the most common monogenic disorders worldwide, and although CRISPR-Cas9 nuclease editing of the BCL11A erythroid enhancer has already reached the clinic, its reliance on double-strand breaks (DSBs) carries genotoxic costs — p53 activation, chromothripsis, and unpredictable indel heterogeneity — that make the field uneasy about scaling the approach further. This review we synthesized peer-reviewed literature on programmable epigenome editing, tracing its conceptual lineage from first-generation zinc finger nucleases and TALENs, through nuclease-active CRISPR-Cas9, toward catalytically dead Cas9 (dCas9) fused to chromatin-modifying effectors such as KRAB, DNMT3A/3L (CRISPRoff), and p300/VPR (CRISPRa). A structured narrative-synthesis methodology, was applied to identify mechanistic, preclinical, and clinical-trial evidence relevant to globin-locus silencing, off-target profiling, and non-viral delivery. The synthesis shows that dCas9-KRAB and CRISPRoff can silence the HS2 enhancer and related regulatory elements with a durability that persists across erythroid differentiation, that deep-learning tools such as EpiCas-DL meaningfully improve on-target guide selection by incorporating chromatin accessibility, and that virus-like particles (VLPs) delivering pre-assembled ribonucleoprotein complexes offer a transient, low-genotoxicity alternative to viral vectors that routinely exceed the ~4.7 kb AAV packaging ceiling. Across fourteen preclinical applications and nine active human trials extracted from the literature, epigenome editing consistently traded a measure of editing permanence for a marked reduction in genotoxic risk. We conclude that specificity — not raw editing efficiency — is now the rate-limiting variable for translating epigenome editors into a durable, one-time SCD therapy, and we outline where chromatin-context modeling and delivery engineering are likely to matter most over the next several years.
Keywords: Sickle cell disease; CRISPR-Cas9; Epigenome editing; dCas9-KRAB; CRISPRoff; Hematopoietic stem and progenitor cells; Virus-like particle delivery
Anzalone, A. V., Randolph, P. B., Davis, J. R., Sousa, A. A., Koblan, L. W., Levy, J. M., Chen, P. J., Wilson, C., Newby, G. A., Raguram, A., & Liu, D. R. (2019). Search-and-replace genome editing without double-strand breaks or donor DNA. Nature, 576(7785), 149–157. https://doi.org/10.1038/s41586-019-1711-4
Banskota, S., Raguram, A., Suh, S., Du, S. W., Davis, J. R., Choi, E. H., Wang, X., Nielsen, S. C., Newby, G. A., Randolph, P. B., & Liu, D. R. (2022). Engineered virus-like particles for efficient in vivo delivery of therapeutic proteins. Cell, 185(2), 250–265. https://doi.org/10.1016/j.cell.2021.12.021
Chen, Y., Luo, S., & Liang, P. (2024). Current therapies for osteoarthritis and prospects of CRISPR-based genome, epigenome, and RNA editing in osteoarthritis treatment. Journal of Genetics and Genomics, 51(2), 159–183. https://doi.org/10.1016/j.jgg.2023.07.023
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., & Zhang, F. (2013). Multiplex genome engineering using CRISPR/Cas systems. Science, 339(6121), 819–823. https://doi.org/10.1126/science.1231143
Diamantopoulos, M. A., Boti, M. A., Kanellopoulos, E., & Scorilas, A. (2026). MicroRNAs in breast cancer: Biological functions and technologies for experimental and therapeutic applications. Cancers, 18(2708), 1–40.
Fayed, S., Amer, S., Badawy, M., Bou Malhab, L., Omran, N., Khoder, G., Ghemrawi, R., Haider, M., Hamoudi, R., & Harati, R. (2026). The role of CRISPR and its therapeutic applications in glioblastoma. International Journal of Molecular Sciences, 27(2008), 1–34.
Fischer, C., Bashtrykov, P., & Jeltsch, A. (2026). Engineering epigenome editing tools: Current progress and future perspectives. Current Opinion in Biomedical Engineering, 38, 100662. https://doi.org/10.1016/j.cobme.2026.100662
Fontana, L., Martinucci, P., Amistadi, S., Felix, T., Mombled, M., Tachtsidi, A., Corre, G., Chalumeau, A., Hardouin, G., Martin, J., et al. (2025). Multiplex base editing of BCL11A regulatory elements to treat sickle cell disease. Cell Reports Medicine, 6(10), 101379. https://doi.org/10.1016/j.cellmed.2025.101379
Gilbert, L. A., Larson, M. H., Morsut, L., Liu, Z., Brar, G. A., Torres, S. E., Stern-Ginossar, N., Brandman, O., Whitehead, E. H., Doudna, J. A., et al. (2013). CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. Cell, 154(2), 442–451. https://doi.org/10.1016/j.cell.2013.06.044
Gladue, D. P., & O'Mahony, A. (2025). CRISPR treatments for AI-designed synthetic viruses: Rapid programmable countermeasures for emerging and engineered viruses. Viruses, 17(1588), 1–15. https://doi.org/10.3390/v17121588
Hernandez Rodriguez, S., & Yokota, T. (2026). Building CRISPR-based gene-editing platforms for personalized medicine: The next step in interventional genetics. Genes, 17(6), 720. https://doi.org/10.3390/genes17060720
Horlbeck, M. A., Witkowsky, L. B., Guglielmi, B., Replogle, J. M., Gilbert, L. A., Villalta, J. E., Torigoe, S. E., Tjian, R., & Weissman, J. S. (2016). Nucleosomes impede Cas9 access to DNA in vivo and in vitro. eLife, 5, e12677. https://doi.org/10.7554/eLife.12677
Huang, H., Zhang, W., Zhang, J., Zhao, A., & Jiang, H. (2023). Epigenome editing based on CRISPR/dCas9(p300) facilitates transdifferentiation of human fibroblasts into Leydig-like cells. Experimental Cell Research, 425(1), 113551. https://doi.org/10.1016/j.yexcr.2023.113551
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012). A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science, 337(6096), 816–821. https://doi.org/10.1126/science.1225829
Ju, S., Lee, J. H., Yang, J., Jeong, T. Y., Choi, C. G., Lee, Y., Cha, S., Park, J., Kim, S. P., Kim, S., Seong, J. K., Lee, H., & Kim, K. (2026). A versatile VLP-mediated CRISPR-RNP platform for precise genome editing and durable epigenome silencing in cancer. Molecular Therapy: Nucleic Acids, 37, 102978. https://doi.org/10.1016/j.omtn.2026.102978
Kaymaz, A. Y., Bora-Akoglu, G., Yurter, H. E., & Grunseich, C. (2026). Gene targeted therapies for neurodegenerative disorders: Strategies and implications in ALS and SMA. Genes, 17(419), 1–28.
Kuroda, T., & Yokota, T. (2026a). RNA therapeutics targeting skeletal muscle: Emerging antisense and gene-modifying strategies. Biomolecules, 16(5), 794. https://doi.org/10.3390/biom16050794
Kuroda, T., & Yokota, T. (2026b). The role of CRISPR-based therapies in Duchenne muscular dystrophy. Cells, 15(852), 1–32.
Levesque, S., & Bauer, D. E. (2025). CRISPR-based therapeutic genome editing for inherited blood disorders. Nature Reviews Drug Discovery, 24(12), 907–925. https://doi.org/10.1038/s41573-025-00123-x
Li, Y., Ma, S., & Fei, T. (2026). CRISPR applications in Alzheimer's disease: From high-throughput genetic screening to precision editing and CNS delivery. International Journal of Molecular Sciences, 27(3371), 1–19.
Mais, R., Kumar, A., Ahmetaj, A., Burgos-Crespo, G., Sanchez, M. M., Roxas, D. C., Dcosta, C., Ilyas, A., Hadjiargyrou, M., & Zanganeh, S. (2026). Nanoengineering systems for gene therapy: Mechanisms, modalities, and future directions. International Journal of Molecular Sciences, 27(5988), 1–23.
McCutcheon, S. R., Rohm, D., Iglesias, N., & Gersbach, C. A. (2024). Epigenome editing technologies for discovery and medicine. Nature Biotechnology, 42, 1199–1217.
Menna, F., Pinelli, C., De Luca, L., Meduri, A., Baldascino, A., Lupo, S., & Vingolo, E. M. (2026). From genetic diagnosis to therapeutic implementation in retinal diseases: Translational advances and persistent bottlenecks. Biomedicines, 14(782), 1–25.
Neumann, E. N., Bertozzi, T. M., Wu, E., Serack, F., Harvey, J. W., Brauer, P. P., & Kamath, N. (2024). Brainwide silencing of prion protein by AAV-mediated delivery of an engineered compact epigenetic editor. Science, 384(6699), ado7082. https://doi.org/10.1126/science.ado7082
Nunez, J. K., Chen, J., Pommier, G. C., Cogan, J. Z., Replogle, J. M., Adriaens, C., Ramadoss, G. N., Shi, Q., Hung, K. L., Samelson, A. J., et al. (2021). Genome-wide programmable transcriptional memory by CRISPR-based epigenome editing. Cell, 184(10), 2503–2519. https://doi.org/10.1016/j.cell.2021.03.025
Pattali, R. K., Divekar, N. S., & Nuñez, J. K. (2026). Next generation technologies for CRISPR-based epigenome and transcriptional modulation. Current Opinion in Biomedical Engineering, 38, 100654. https://doi.org/10.1016/j.cobme.2026.100654
Pulecio, J., Verma, N., Mejía-Ramírez, E., Huangfu, D., & Raya, A. (2017). CRISPR/Cas9-based engineering of the epigenome. Cell Stem Cell, 21(4), 431–447. https://doi.org/10.1016/j.stem.2017.09.006
Rodriguez, S. H., & Yokota, T. (2026). Building CRISPR-based gene-editing platforms for personalized medicine: The next step in interventional genetics. Genes, 17(6), 720. https://doi.org/10.3390/genes17060720
Rohm, D., Black, J. B., McCutcheon, S. R., Barrera, A., Berry, S. S., Morone, D. J., Nuttle, X., de Esch, C. E., Talkowski, M. E., Iglesias, N., & Gersbach, C. A. (2025). Activation of the imprinted Prader-Willi syndrome locus by CRISPR-based epigenome editing. Cell Genomics, 5(1), 100770. https://doi.org/10.1016/j.xgen.2025.100770
Sazdova, I., Gagov, H., Hadzi-Petrushev, N., Konaktchieva, M., Konakchieva, R., & Mladenov, M. (2026). Advanced studies in molecular and metabolic mechanisms of diabetes: Pathogenic crosstalk, biomarkers, and translational therapeutics. Applied Sciences, 16(3027), 1–50. https://doi.org/10.3390/app16063027
Shahannaz, D. C., & Sugiura, T. (2026). Next-generation metabolic reprogramming in iPSC-derived cardiomyocytes: CRISPR-EV synergy for precision cardiac regeneration. Biomolecules, 16(467), 1–26.
Siringan, M. J., Chen, X., & Huo, J. (2026). RNA-loaded nanoparticles for targeted lung delivery. Biomedicines, 14(1069), 1–24. https://doi.org/10.3390/biomedicines14041069
Stadager, J., Bernardini, C., Hartmann, L., Traube, F. R., Jude, J., & Rathert, P. (2025). CRISPR GENome and epigenome engineering improves loss-of-function genetic-screening approaches. Cell Reports Methods, 5(1), 101078. https://doi.org/10.1016/j.crmeth.2025.101078
Sterckel, S., Chávez Martínez, I. L., & Schwach, V. (2026). CRISPR and the future of cardiac disease therapy: A new genetic frontier. International Journal of Molecular Sciences, 27(3641), 1–23.
Stover, J. D., Farhang, N., Berrett, K. C., Gertz, J., Lawrence, B., & Bowles, R. D. (2017). CRISPR epigenome editing of AKAP150 in DRG neurons abolishes degenerative IVD-induced neuronal activation. Molecular Therapy, 25(9), 2014–2027. https://doi.org/10.1016/j.ymthe.2017.06.010
Stover, J. D., Lawrence, B., & Bowles, R. D. (2021). Degenerative IVD conditioned media and acidic pH sensitize sensory neurons to cyclic tensile strain. Journal of Orthopaedic Research, 39(6), 1192–1203. https://doi.org/10.1002/jor.24682
Stover, J. D., Trone, M. A., Lawrence, B., & Bowles, R. D. (2023). Multiplex epigenome editing ion channel expression in nociceptive neurons. JOR Spine, 6(1), e1253. https://doi.org/10.1002/jsp2.1253
Tariq, A., Naz, I., Arshad, F., Chinnappan, R., Mir, T. A., Khan, M. I., & Yaqinuddin, A. (2026). Real-time and spatially resolved epigenetic dynamics tracking beyond DNA methylation via live-cell epigenetic sensors in 3D systems. Biosensors, 16(188), 1–30.
Thakore, P. I., D'Ippolito, A. M., Song, L., Safi, A., Shivakumar, N. K., Kabadi, A. M., Bledsoe, P., Reddy, T. E., Crawford, G. E., & Gersbach, C. A. (2015). Highly specific epigenome editing by CRISPR-Cas9 repressors for silencing of distal regulatory elements. Nature Methods, 12(12), 1143–1149. https://doi.org/10.1038/nmeth.3630
Woronkowicz, M., Thomas, M. N., Saram, S. J., Carr, A. J. F., Alonso-Carriazo Fernandez, A., Butt, Z., Skopinski, P., & Ramsden, C. M. (2026). CRISPR and beyond: Genome-editing strategies in retinal stem cell research. Cells, 15(489), 1–42. https://doi.org/10.3390/cells15030489
Wu, L., Li, Z., Zhu, J., Sun, Z., Yan, L., Luo, M., Chen, H., & Yin, Y. (2026). Engineering the gut microbiome: Emerging genome-editing strategies and therapeutic applications. Microorganisms, 14(1174), 1–32. https://doi.org/10.3390/microorganisms14061174
Xu, J., Zhou, J., Ren, Z., Xu, J., Zhang, J., & Chen, Y. E. (2025). Gene editing therapy ready for cardiovascular diseases: Opportunities, challenges, and perspectives. Cells, 15(134), 1–38.
Yang, Q., Wu, L., Meng, J., et al. (2023). EpiCas-DL: Predicting sgRNA activity for CRISPR-mediated epigenome editing by deep learning. Computational and Structural Biotechnology Journal, 21, 202–211. https://doi.org/10.1016/j.csbj.2022.11.034
Yoon, B., Kim, J. A., & Kang, Y. K. (2026). CRISPR-Cas-mediated reprogramming strategies to overcome antimicrobial resistance. Pharmaceutics, 18(95), 1–21.
Next-generation RNA medicine: antisense, siRNA, mRNA, and CRISPR systems with organ-targeted delivery
Novel Biomarkers and Therapeutic Avenues for Precision Oncology and Effective Treatment Strategies
A Review of Pathophysiology, Prevalence, Diagnosis, Therapeutic Approaches, and Nutritional Considerations in Sickle Cell Disease